Elutia (ELUT) Financials: History & Chart

Elutia Inc(ELUT)

Biotechnology · Gaithersburg, MD

$0.82-0.00 (-0.21%)

Delayed quote: Oct 6, 2026, 11:34 AM EDT

About Elutia Inc

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.

Gaithersburg, MD

26 employees

elutia.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: C. Randal Mills

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	12.13M	2.43M	3.11M	3.27M	3.32M	6.26M	6.03M	5.47M	5.92M
Cost of Goods Sold	5.12M	980K	1.31M	1.36M	1.47M	3.21M	3.57M	3.14M	3.18M
Gross Profit	7.02M	1.45M	1.80M	1.91M	1.85M	3.06M	2.46M	2.32M	2.74M
Gross Profit Margin	57.8%	59.6%	57.9%	58.5%	55.8%	48.8%	40.7%	42.5%	46.3%
Total Operating Expenses	30.56M	9.40M	7.54M	7.41M	6.21M	12.93M	10.38M	10.76M	12.97M
Research & Development	6.80M	2.53M	1.97M	1.22M	1.09M	1.46M	905K	834K	778K
Selling, General & Administrative	16.86M	4.82M	5.57M	1.35M	5.12M	7.47M	6.90M	7.31M	7.51M
Operating Income (EBIT)	-23.55M	-7.96M	-5.74M	-5.49M	-4.36M	-9.88M	-7.92M	-8.43M	-10.23M
Operating Margin	-194.0%	-327.9%	-184.4%	-167.9%	-131.1%	-157.7%	-131.4%	-154.2%	-172.7%
Income Before Tax (EBT)	-22.36M	-7.64M	-7.82M	-6.52M	-375K	-9.60M	-3.92M	-9.06M	1.29M
Interest Income	35K	35K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	-3.48M	N/A	-108K	-3.63M	265K	518K	1.08M	1.07M	1.13M
Other Income/Expense	1.19M	319K	-2.08M	-1.03M	3.98M	273K	4.00M	-627K	11.52M
Net Income	51.81M	-7.65M	-7.47M	70.79M	-3.87M	-9.61M	-3.93M	-9.06M	1.29M
Income Tax Expense	75K	8K	70K	-11K	8K	8K	8K	2K	8K
Net Profit Margin	426.9%	-315.0%	-239.9%	2164.2%	-116.4%	-153.4%	-65.2%	-165.7%	21.7%
EBITDA	-21.84M	-7.61M	-5.41M	-5.19M	-3.63M	-8.98M	-7.05M	-7.57M	-9.37M
EBITDA Margin	-180.0%	-313.5%	-173.8%	-158.8%	-109.1%	-143.4%	-117.0%	-138.4%	-158.2%
Depreciation & Amortization	1.70M	349K	330K	297K	728K	892K	868K	863K	862K
EPS Basic	1.30	-0.18	-0.17	1.66	-0.01	-0.23	-0.10	-0.26	-0.36
EPS Diluted	0.94	-0.18	-0.17	1.48	-0.19	-0.26	-0.21	-0.26	-0.33
Weighted Average Basic Shares	43.62M	43.62M	43.00M	42.72M	40.97M	41.78M	38.62M	34.85M	32.52M
Weighted Average Diluted Shares	43.62M	43.62M	43.00M	47.24M	45.49M	46.31M	42.91M	34.85M	35.52M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	12.29M	24.38M	24.75M	23.85M	47.39M	42.68M	42.90M	39.04M
Cost of Goods Sold	5.70M	13.67M	13.69M	12.21M	28.37M	22.12M	23.13M	23.09M
Gross Profit	6.60M	10.71M	11.05M	11.64M	19.02M	20.56M	19.77M	15.95M
Gross Profit Margin	53.7%	43.9%	44.7%	48.8%	40.1%	48.2%	46.1%	40.8%
Total Operating Expenses	25.01M	46.36M	41.58M	46.83M	42.05M	34.16M	28.18M	24.17M
Research & Development	4.16M	3.79M	4.40M	7.73M	9.27M	5.95M	2.40M	2.48M
Selling, General & Administrative	20.84M	31.20M	27.19M	33.90M	32.51M	28.21M	25.78M	21.68M
Operating Income (EBIT)	-18.41M	-35.65M	-30.53M	-35.19M	-23.03M	-13.60M	-8.41M	-8.22M
Operating Margin	-149.8%	-146.3%	-123.4%	-147.5%	-48.6%	-31.9%	-19.6%	-21.1%
Income Before Tax (EBT)	-15.86M	-54.12M	-41.22M	-36.15M	-24.78M	-21.80M	-11.91M	-11.54M
Interest Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	-387K	4.78M	5.80M	5.12M	5.32M	5.63M	5.38M	5.52M
Other Income/Expense	2.55M	-18.47M	-10.70M	-959K	-1.75M	-8.20M	-3.50M	-3.32M
Net Income	53.38M	-53.95M	-37.66M	-32.90M	-24.83M	-21.82M	-11.94M	-11.57M
Income Tax Expense	13K	7K	28K	34K	55K	26K	30K	26K
Net Profit Margin	434.2%	-221.3%	-152.2%	-137.9%	-52.4%	-51.1%	-27.8%	-29.6%
EBITDA	-15.63M	-32.20M	-27.02M	-31.46M	-19.30M	-9.73M	-4.55M	-4.42M
EBITDA Margin	-127.1%	-132.1%	-109.2%	-131.9%	-40.7%	-22.8%	-10.6%	-11.3%
Depreciation & Amortization	2.79M	3.45M	3.51M	3.73M	3.73M	3.86M	3.86M	3.80M
EPS Basic	1.29	-1.86	-2.07	-2.38	-2.38	-2.13	-1.12	-1.08
EPS Diluted	N/A	-1.86	-2.07	-2.38	-2.38	-2.13	-1.12	-1.08
Weighted Average Basic Shares	41.42M	29.07M	18.16M	13.83M	10.44M	10.23M	10.67M	10.67M
Weighted Average Diluted Shares	45.94M	29.07M	18.16M	13.83M	10.44M	10.23M	10.67M	10.67M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.